Ryan McDonald | Authors

December 11, 2022

Fast and durable response were seen in patients with Waldenström Macroglobulinemia who received the combination of ibrutinib and venetoclax.

December 10, 2022

Pretreatment with Obinutuzumab aids fixed-duration regimen of glofitamab in high complete responses among a group of heavily pretreated patients with relapsed or refractory mantle cell lymphoma.

September 11, 2022

Multiple blood-based biomarkers suggest potential responses to treatment with maintenance avelumab for patients with advanced or metastatic urothelial carcinoma from the phase 3 JAVELIN Bladder 100 trial, according to an exploratory analysis presented at the European Society for Medical Oncology Congress 2022.

June 09, 2022

In patients with previously untreated, locally advanced stage III non–small cell lung cancer, continued benefit from pembrolizumab with concurrent chemoradiation followed by additional pembrolizumab was observed after more than 2 years of follow-up.

June 06, 2022

Lurbinectedin in combination with pembrolizumab in the second-line shows promising safety and efficacy in relapsed small cell lung cancer

June 04, 2022

With roughly 5 years of follow-up, outcomes were more favorable with acalabrutinib with or without obinutuzumab vs obinutuzumab and chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia.